GTS Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-102,700
Closed -$12.2M 3155
2024
Q3
$12.2M Sell
102,700
-7,700
-7% -$1.03M 0.03% 426
2024
Q2
$15.8M Buy
110,400
+18,100
+20% +$2.4M 0.03% 319
2024
Q1
$11.9M Buy
92,300
+40,600
+79% +$4.83M 0.02% 437
2023
Q4
$5.35M Sell
51,700
-89,600
-63% -$8.86M 0.01% 952
2023
Q3
$12.8M Buy
+141,300
New +$12.4M 0.02% 495

Other funds holding NVO

GTS Securities's NVO Position: Q2 2026 in Review

GTS Securities opened a new position in Novo Nordisk (NVO) in Q2 2026: 75,048 shares worth $3.6M. The stake represents 0.08% of the portfolio and ranks #153 among its holdings. This is a return to the name: GTS Securities previously reported a position in NVO as recently as Q4 2025.

GTS Securities first reported a position in NVO in Q2 2023 and has held it in 10 quarters since. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • GTS Securities held 75,048 shares of Novo Nordisk worth $3.6M as of Q2 2026.
  • Novo Nordisk was a new GTS Securities position in Q2 2026.
  • Novo Nordisk made up 0.08% of GTS Securities's portfolio in Q2 2026, its #153 holding.
  • GTS Securities first reported a position in Novo Nordisk in Q2 2023 and has held it in 10 quarters since.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.